

CollPlant Completes Private Placement of USD 2 Million

Option Provided for Up to an Additional USD 1 Million Investment by July 15, 2015

Yehiel Tal: *"This financing, combined with CollPlant's recent ADR registration, is consistent with the Company's plans to expand its U.S. presence, both commercially and financially."*

Option Provided for Up to an Additional USD 1 Million Investment by Mid-July 2015

Rehovot, June 4, 2015, CollPlant (Tel-Aviv: CLPT; OTCQX: OTCM), a regenerative medicine company focused on developing and commercializing tissue repair products initially for the orthobiologics and advanced wound care markets, announced today that it will raise approximately USD 2 million in gross proceeds through a private placement of approximately 17.2 million shares of Common Stock and warrants to purchase up to approximately 8.6 million shares. The purchase price for the common stock is NIS 0.449 which is based upon the closing share price on June 1, 2015. The investors will receive a three-year warrant to purchase one share of common stock for every two shares purchased in the placement at an exercise price of NIS 0.80 per share. The private placement is expected to close during June, 2015, after regulatory approval for the issuance of the shares is obtained.

In addition to the preliminary investment, investors were given an option for a further investment of USD 1 million, exercisable until July 15, 2015. The exercise price shall be the higher of: 1) the average of the five trading days preceding the exercise notice, 2) the share price in the preliminary investment – NIS 0.449 per share. Subject to the exercise of the additional investment, investors will receive options at the scope of 50% of the quantity of shares exercised in the additional investment, with each option exercisable at a price that is NIS 0.35 higher than the share price set when exercising the additional investment option.

Yehiel Tal, CEO of CollPlant: "This current financing, combined with CollPlant's ADR's registration, completed in recent months, provides additional exposure and support within the U.S. market, as the Company builds its infrastructure for North American business operations. Concurrently, the Company is working diligently to achieve its stated regulatory and business objectives, including securing CE approvals for its first two products as well as plans for their commercial launch in the European Market."

About CollPlant

CollPlant is a clinical-stage regenerative medicine company leveraging its proprietary, plant-based rhCollagen technology for the development and commercialization of tissue repair products, initially for the orthobiologics and advanced wound care markets. The Company's cutting-edge technology is designed to generate and process proprietary recombinant human collagen (rhCollagen), among other patent-protected recombinant proteins. Given that CollPlant's rhCollagen is identical to the type I collagen produced by the human body, it offers significant advantages compared to currently marketed tissue-derived collagen, including improved biofunctionality, superior homogeneity and reduced risk of immune



response. The Company's broad development pipeline includes biomaterials indicated for orthopedics and advanced wound healing. Lead products include: Vergenix™STR (Soft Tissue Repair Matrix), for the treatment of tendinopathy; Vergenix™FG (Flowable Gel) wound filler, for treatment of acute and chronic wounds, and; Vergenix™BVF (Bone Void Filler), for use in spinal fusion procedures and trauma. CollPlant's business strategy includes proprietary development and manufacturing of tissue repair products and their commercialization and distribution, together with leading third parties, alongside alliances with leading companies for joint development, manufacturing and marketing of additional products.

For more information about CollPlant, visit <http://www.collplant.com>

Contact at CollPlant:

Eran Rotem

Chief Financial Officer

Tel: + 972-73-2325600/612

Email: Eran@collplant.com

Contact at Rx Communications Group, LLC:

Paula Schwartz (for US Investors)

Senior Vice President

Tel: 917-322-2216

Email: pschwartz@rxir.com